BioNexus Gene Lab Corp.
BGLC
$5.30
-$0.12-2.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.01% | -5.21% | -2.66% | -10.42% | -11.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.01% | -5.21% | -2.66% | -10.42% | -11.35% |
| Cost of Revenue | 3.74% | -5.35% | -2.61% | -10.32% | -12.24% |
| Gross Profit | 5.70% | -4.35% | -3.02% | -11.08% | -5.40% |
| SG&A Expenses | 2.29% | -34.10% | -42.72% | -43.86% | 64.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 234.29% | 2,136.47% | 1,877.91% | 90.76% | 145.34% |
| Total Operating Expenses | 7.31% | -9.41% | -9.97% | -18.51% | 10.24% |
| Operating Income | -18.44% | 22.43% | 33.48% | 47.29% | -518.34% |
| Income Before Tax | -42.55% | 19.09% | 38.84% | 69.24% | -303.02% |
| Income Tax Expenses | -174.18% | -164.45% | -83.26% | -78.85% | 145.45% |
| Earnings from Continuing Operations | -33.00% | 20.49% | 39.20% | 69.57% | -291.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.00% | 20.49% | 39.20% | 69.57% | -291.86% |
| EBIT | -18.44% | 22.43% | 33.48% | 47.29% | -518.34% |
| EBITDA | -17.64% | 23.95% | 35.13% | 49.00% | -649.83% |
| EPS Basic | -22.96% | 27.34% | 44.76% | 72.45% | -241.14% |
| Normalized Basic EPS | -10.04% | 33.76% | 45.79% | 58.66% | -378.85% |
| EPS Diluted | -22.96% | 27.34% | 44.76% | 72.45% | -241.14% |
| Normalized Diluted EPS | -10.04% | 33.76% | 45.79% | 58.66% | -378.85% |
| Average Basic Shares Outstanding | 2.88% | 7.36% | 12.28% | 18.15% | 20.78% |
| Average Diluted Shares Outstanding | 2.88% | 7.36% | 12.28% | 18.15% | 20.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |